The Online Investor
Biotechnology M&A image Biotechnology M&A » By The Online Investor Staff, updated Fri., Mar. 29, 7:00 AM Recent mergers and acquisitions in the Biotechnology M&A category.

Slide #48. Cubist Pharmaceuticals, Inc. Trius Therapeutics

Acquirer: Cubist Pharmaceuticals, Inc. (CBST)
Acquiree: Trius Therapeutics (TSRX)
Details: Cubist Pharmaceuticals, Inc. (NASDAQ:CBST) today announced that it has completed the previously announced acquisition of Trius Therapeutics, Inc. (NASDAQ:TSRX) for an aggregate upfront cash consideration of approximately $704 million. Effective today, Trius common stock will cease to be traded on the NASDAQ.

Cubist Pharmaceuticals is a biopharmaceutical company focused on the research, development and commercialization of therapies to treat patients who are hospitalized or are being treated in other acute care settings. Co. has three marketed products: CUBICIN® for the treatment of certain Gram-positive bacteria and for certain bloodstream infections; DIFICID® for the treatment of Clostridium difficile-associated diarrhea (CDAD); and ENTEREG® to accelerate gastrointestinal recovery. Co. has four late-stage product candidates: Tedizolid phosphate and Ceftolozane/tazobactam for treatment of Gram-positive bacterial infections; Surotomycin for CDAD; and Bevenopran for opioid-induced constipation.

Open the CBST Page at The Online Investor »

Cubist Pharmaceuticals is a biopharmaceutical company focused on the research, development and commercialization of therapies to treat patients who are hospitalized or are being treated in other acute care settings. Co. has three marketed products: CUBICIN® for the treatment of certain Gram-positive bacteria and for certain bloodstream infections; DIFICID® for the treatment of Clostridium difficile-associated diarrhea (CDAD); and ENTEREG® to accelerate gastrointestinal recovery. Co. has four late-stage product candidates: Tedizolid phosphate and Ceftolozane/tazobactam for treatment of Gram-positive bacterial infections; Surotomycin for CDAD; and Bevenopran for opioid-induced constipation.

Open the TSRX Page at The Online Investor »

Company Name: 
Cubist Pharmaceuticals Inc.
Website: 
www.cubist.com
Sector: 
Biotechnology
Company Name: 
Trius Therapeutics Inc.
Website: 
www.triusrx.com
Sector: 
Drugs & Pharmaceuticals
 

Quotes delayed 20 minutes

Email EnvelopeFree Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts

Biotechnology M&A - Slide 48 of 83 Page | www.TheOnlineInvestor.com

Copyright © 1998 - 2024, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.